Highlights
● MetS is associated with significant hepatic fibrosis and steatosis in a cohort of patients with biopsy-proven NASH.
● NASH patients with MetS deserve more aggressive intervention and treatment.
● Greater awareness and risk stratification strategies are warranted to address the increasing burden of NASH.